Kolja I. Ortmann

Merger Control, Foreign Direct Investment and Foreign Subsidies Regulation

• Amgen on its $28.3 billion acquisition of Horizon Therapeutics
• Baxter on its $3.8 billion sale of its Vantive kidney care segment to Carlyle
• Biohaven Pharmaceutical on its $11.6 billion acquisition by Pfizer
• Bosch on its $8 billion acquisition of Johnson Controls’ and Hitachi’s HVAC business as well as the acquisition of a minority share in Swedish Husqvarna
• Flix in relation to an investment by EQT and Kühne
• home24 in relation to its voluntary public takeover by Austrian-based furniture retail company XXXLutz
• Kering in relation to its acquisitions of Maui Jim and Creed

• Lundin Mining Corporation in connection with its and BHP’s definitive agreement with Filo Corp. to jointly acquire 100% of Filo’s issued and outstanding common shares
• Majorel (owned by Bertelsmann and Saham) in connection with the voluntary public takeover by Teleperformance and the (abandoned) merger with Sitel
• Merck KGaA in its $11.3 billion acquisition of Bio-Techne and its $3.9 billion acquisition of Springworks Therapeutics
• Schaeffler on the full range of competition matters, including in relation to the Vitesco restructuring
• Seagen on its $43 billion acquisition by Pfizer
• Triton in its $13.3 billion acquisition by Brookfield Infrastructure Partners
• VMware (and its co-owner Silver Lake) on the merger control and FDI aspects of its $69 billion acquisition by Broadcom
• Zalando in relation to its voluntary public takeover of ABOUT YOU

Investigations, Conduct and Digital Markets Act

Mr. Ortmann has significant experience advising clients on antitrust investigations and conduct issues in Europe and in the US, as well as the EU’s platform regulation DMA, including counseling clients that may be found to hold a dominant position, defending targets of investigations and representing complainants in such investigations (including Circana, Dolby, Intel, K+S and Sisvel).